Sum Up The Parts: VBK Could Be Worth $307By The Online Investor Staff, Tuesday, May 24, 7:19 AM ETLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (NYSE:VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $306.68 per unit. With VBK trading at a recent price near $207.33 per unit, that means that analysts see 47.92% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of VBK's underlying holdings with notable upside to their analyst target prices are Lyell Immunopharma Inc (NASDAQ:LYEL), (NASDAQ:RELY), and Nkarta Inc (NASDAQ:NKTX). Although LYEL has traded at a recent price of $4.28/share, the average analyst target is 258.25% higher at $15.33/share. Similarly, RELY has 255.53% upside from the recent share price of $10.36 if the average analyst target price of $36.83/share is reached, and analysts on average are expecting NKTX to reach a target price of $44.33/share, which is 247.17% above the recent price of $12.77. Below is a twelve month price history chart comparing the stock performance of LYEL, RELY, and NKTX:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Find the right mix of model portfolios today at PortfolioChannel.com
This Article's Word Cloud:
Analyst
Below
ETFs
FREEGet
Growth
Immunopharma
LYEL
Lyell
NKTX
Nkarta
RELY
Small
Target
Upside
Vanguard
With
Zacks
about
above
analyst
analysts
average
background
based
border
bottom
color
data
font
from
have
hctblstyle
holdings
implied
latest
mdash
month
padding
price
prices
recent
report
research
share
target
targets
that
trading
underlying
upside
|
Start slideshow: